Table 2 Correlations of CINSARC classes with clinicopathological characteristics in Luminal B breast cancer patients.
From: The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer
Characteristics | CINSARC classes | ||||
|---|---|---|---|---|---|
N | Low-risk | High-risk | p-value | ||
Patients’ age | 0.233 | ||||
≤50 | 283 | 104 (23%) | 179 (26%) | ||
>50 | 843 | 345 (77%) | 498 (74%) | ||
Pathological tumor type | 0.178 | ||||
Ductal | 723 | 289 (80%) | 434 (81%) | ||
Lobular | 76 | 26 (7%) | 50 (9%) | ||
Other | 96 | 46 (13%) | 50 (9%) | ||
Pathological grade | 3.13E−04 | ||||
1 | 65 | 35 (9%) | 30 (5%) | ||
2 | 427 | 198 (51%) | 229 (42%) | ||
3 | 446 | 156 (40%) | 290 (53%) | ||
Pathological axillary lymph node status | 1.18E−02 | ||||
Negative | 676 | 295 (60%) | 381 (52%) | ||
Positive | 545 | 199 (40%) | 346 (48%) | ||
Pathological tumor size | 0.322 | ||||
pT1 | 398 | 169 (37%) | 229 (33%) | ||
pT2 | 664 | 252 (55%) | 412 (59%) | ||
pT3 | 91 | 38 (8%) | 53 (8%) | ||
Adjuvant chemotherapy | 0.012 | ||||
No | 880 | 375 (83%) | 505 (77%) | ||
Yes | 230 | 77 (17%) | 153 (23%) | ||
Adjuvant hormone therapy | 0.709 | ||||
No | 457 | 188 (42%) | 269 (41%) | ||
Yes | 647 | 258 (58%) | 389 (59%) | ||
Follow-up median, months (min–max) | 1438 | 71 (0–243) | 63 (0–294) | 0.677 | |
DFS event (%) | 1438 | 164 (28%) | 309 (36%) | 9.19E−04 | |
5-year DFS | 1438 | 79% [75–83] | 69% [66–73] | 2.01E−04 | |
